USP25/28 inhibitor AZ1 (AZ1) (AZ1) is an inhibitor of ubiquitin specific protease (USP) 25/28

LpxH-IN-AZ1 is a potent inhibitor of the UDP-2,3-diacylglucosamine pyrophosphate hydrolase, LpxH, and sulfonylpiperazine compounds.LpxH-IN-AZ1 exhibits antimicrobial activity and inhibits Klebsiella pneumoniae with an IC50 of 0.36 μM.

AZ10397767 is a potent CXCR2 antagonist (IC50 = 1 nM). AZ10397767 significantly reduced the numbers of infiltrating neutrophils into both in vitro and in vivo tumor models.

AZ10606120 dihydrochloride is a selectable, potent, high-affinity receptor antagonist with K D values of 1.4 and 19 nM at human and rat P2X 7 receptors, respectively. AZ10606120 dihydrochloride inhibits tumor growth and has anti-angiogenic activity. AZ 10606120 acts as a negative allosteric modulator when bound to a site coupled to the ATP binding site.

AZ12672857 is an inhibitor of EphB4 with IC50 of 1.3 nM. AZ12672857 inhibits cell proliferation of Src transfected 3T3 cells with IC50 of 2 nM and autophosphorylation of EphB4 in transfected CHO-K1 cells with IC50 of 9 nM.

AZ191（IC50 of 17 nM） is an effective and specific DYRK1B inhibitor. The specificity of AZ191 for DYRK1B is about 5- and 110-fold greater over DYRK1A and DYRK2, respectively.

AZ1508, a tubulin inhibitor[1], serves as a drug-linker conjugate for antibody-drug conjugates (ADC) targeting breast and stomach cancer treatment.

AZ12099548 is a transient receptor potential cation channel subfamily V member 1 (TRPV1) antagonist.

AZ12216052 is a GRP8 antagonist with anxiolytic and anti-inflammatory activity and can be used to study obesity and metabolic disorders.

AZ1495 is an oral active inhibitor of Interleukin-1 receptor associated kinase 4 (IRAK4), with IC50 values of 5 nM and 23 nM for IRAK4 and IRAK1, respectively. Which Shows activity in treatment of mutant MYD88L265P diffuse large B-cell lymphoma (DLBCL).

AZ13705339 hemihydrate is a hemihydrate form of AZ13705339, exhibiting high potency and selectivity as a PAK1 inhibitor, demonstrating IC50 values of 0.33 nM for PAK1 and 59 nM for pPAK1. It also shows strong binding affinities with Kd values of 0.28 nM for PAK1 and 0.32 nM for PAK2. This compound is utilized in cancer research.

AZ13705339 is an effective inhibitor of PAK1 with an IC50 of 0.33 nM and a Kd of 0.28 nM. AZ13705339 binds PAK2 with a Kd of 0.32 nM. AZ13705339 can be used in studies about cancers.

AZ12253801 is a type 1 insulin-like growth factor receptor (IGF-1R) inhibitor.

AZ12441970 is an effective agonist of Toll-like receptor 7 (TLR7 agonist).

AZ13483342 is an antagonist of the melanin concentrating hormone receptor 1 (MCH1) with a potential diabetes therapeutic activity.

AZ12601011 is an orally active, selective and potent TGFBR1 kinase inhibitor.AZ12601011 inhibits the release of inflammatory factors, interleukin (IL)-1β, IL-6 and tumor necrosis factor-α, and inhibits the growth of breast tumors.AZ12601011 directly binds to TGF-βR1 and blocks downstream Smad3 activation, which can be used to prevent renal fibrosis.

AZ12419304, also known as GTPL7734, is a bioactive chemical.

AZ14145845 is an in vivo potent and highly selective type I1/2 Mer/Axl bispecific kinase inhibitor.

CRMP2-Ubc9-NaV1.7 inhibitor 194, is a CRMP2-Ubc9-NaV1.7 inhibitor.

Ac32Az19 is a potent, non-toxic, and highly selective inhibitor of Breast Cancer Resistance Protein (BCRP), demonstrating an EC50 of 13 nM in BCRP-overexpressed HEK293/R2 cells.

AZ1366 is a potent tankyrase inhibitor that enhances irinotecan activity in tumors that exhibit elevated tankyrase and irinotecan resistance. Combination AZ1366 and irinotecan achieved greater anti-tumor effects compared to monotherapy. Activity was limited to CRC explants that displayed irinotecan resistance and increased protein levels of tankyrase and NuMA.

AZ11657312 is a P2X7 receptor antagonist.

AZ12971554 is a potent inhibitor of human thrombin. Ki = 0.3nM, Activated partial thromboplastin time (APTT) IC50 = 0.68µM, Ecarin clotting time (ECT) IC50 = 0.16µM in human plasma.

AZ13824374 is a potent and selective ATAD2 inhibitor with anti-proliferative effects in breast cancer. pIC50 values for AZ13824374 against ATAD2 in the ATAD2 FRET and ATAD2 NanoBRET assays were 8.2 and 6.2, respectively.

BAZ1A-IN-1 is a potent BAZ1A inhibitor with the KD value of 0.52 μM for the BAZ1A bromodomain. BAZ1A-IN-1 shows good anti-survival activity against cancer cell lines with high BAZ1A expression, but weak or no activity against cancer cells with low BAZ1A expression.

AZ-1 is an inducer of ABCA1 and apoE. It enhances ABCA1 activity and decreases P2X7 receptor activity. AZ-1 activates endogenous LXR signaling but shows no direct LXRα or LXRβ agonist activity.